Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

Overview of attention for article published in The Lancet, January 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

blogs: 1 blog
policy: 3 policy sources
twitter: 26 X users

patent: 5 patents
facebook: 2 Facebook pages
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 221 Dimensions

Readers on

mendeley: 131 Mendeley

Summary Blogs Policy documents X Patents Facebook Wikipedia Dimensions citations

So far, Altmetric has seen 2 public wall posts from 2 users.

FUNDACION MAXI RODRIGUEZ GIMENEZ Por la VIDA, 12 Oct 2012

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile…

Medicina Familiar, General, Rural y Comunitaria, 17 Feb 2012

On the basis of immunogenicity responses this study provides evidence for an adolescent 4CMenB vaccine schedule of two doses, 1–6…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.